Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.betadrugslimited.com | |
Market Cap | 1,134.43 Cr. | |
Enterprise Value(EV) | 1,137.38 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 31.95 | Trailing Twelve Months Ending 2023-03 |
Price-Earning Ratio (PE) | 36.93 | Trailing Twelve Months Ending 2023-03 |
Industry PE | 38.75 | Trailing Twelve Months Ending 2023-03 |
Book Value / Share | 127.82 | Trailing Twelve Months Ending 2023-03 |
Price to Book Value | 9.23 | Calculated using Price: 1,180.00 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 0.96 Cr. | 9,613,790 Shares |
FaceValue | 10 | |
About Beta Drugs Ltd. | ||
Beta Drugs is pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers. Beta Drugs is primarily engaged in the manufacturing of oncology products. The products include anti-cancer tablets, capsules, injections and lyophilized injections. Company has portfolio of over 50 products which is used for the treatment of various cancer diseases. Beta Drugs is a part of Adley Group, which was founded in the year 1985. Company's manufacturing unit is located at Solan, Himachal Pradesh. |
1 Day |
|
+0.25% |
1 Week |
|
+5.29% |
1 Month |
|
+21.49% |
3 Month |
|
+17.43% |
6 Month |
|
+59.46% |
1 Year |
|
+62.95% |
2 Year |
|
+126.92% |
5 Year |
|
+1422.58% |
10 Year |
|
6 years | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 20.57 | 21.79 | 19.21 | 18.65 | 30.85 | 28.55 | |
Return on Capital Employed (%) | 19.36 | 18.41 | 20.71 | 22.17 | 36.38 | 33.94 | |
Return on Assets (%) | 13.64 | 12.10 | 9.82 | 10.26 | 17.53 | 16.74 |
Particulars | 7 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 33 | 41 | 57 | 69 | 92 | 123 | 142 | |
Non Curr. Liab. | 3 | 9 | 13 | 15 | 16 | 11 | 11 | |
Curr. Liab. | 14 | 33 | 38 | 37 | 55 | 70 | 83 | |
Minority Int. | ||||||||
Equity & Liab. | 50 | 83 | 108 | 120 | 163 | 204 | 236 | |
Non Curr. Assets | 17 | 39 | 51 | 49 | 60 | 70 | 72 | |
Curr. Assets | 32 | 44 | 57 | 71 | 103 | 134 | 164 | |
Misc. Exp. not W/O | ||||||||
Total Assets | 50 | 83 | 108 | 120 | 163 | 204 | 236 |
Particulars | 6 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Net Sales | 51 | 66 | 91 | 116 | 184 | 227 | |
Other Income | 0 | 0 | 0 | 1 | 1 | 1 | |
Total Income | 51 | 66 | 91 | 117 | 185 | 228 | |
Total Expenditure | -41 | -54 | -73 | -91 | -141 | -174 | |
PBIDT | 10 | 12 | 18 | 25 | 43 | 54 | |
Interest | -1 | -1 | -3 | -2 | -2 | -2 | |
Depreciation | -2 | -3 | -4 | -7 | -7 | -10 | |
Taxation | 0 | 0 | -3 | -4 | -9 | -10 | |
Exceptional Items | |||||||
PAT | 7 | 8 | 9 | 12 | 25 | 31 | |
Minority Interest | |||||||
Share Associate | |||||||
Other Related Items | |||||||
Consolidated Net Profit | 7 | 8 | 9 | 12 | 25 | 31 | |
Adjusted EPS | 8 | 9 | 10 | 12 | 26 | 32 |
Particulars | 6 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 17 | 0 | 8 | 19 | 30 | 23 | |
Cash Fr. Inv. | -11 | -21 | -15 | -6 | -22 | -19 | |
Cash Fr. Finan. | 5 | 12 | 9 | -8 | -1 | -2 | |
Net Change | 12 | -9 | 2 | 5 | 7 | 2 | |
Cash & Cash Eqvt | 12 | 3 | 5 | 10 | 17 | 19 |
No Corporate Announcement found. |
Fri, 01 Dec 2023 |
|
|
|
|
|